Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands ...

explained how bispecific antibodies work, and what patients with cancer can expect directly after treatment and longer term. A lot of people are starting to be a little bit more familiar with ...

This report evaluates the industry landscape of PD-1xVEGF(R) and PD-L1xVEGF bispecific ... antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug ...

BNT324, a bispecific antibody candidate under development by BioNTech (NASDAQ:BNTX) that is seen as critical to the biotech's future success, will compete favorably against rival Summit Therapeutics' ...

Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.

Under the terms of the agreement, VERAXA will initiate a novel bispecific antibody drug conjugate ... changes to the proposed structure of the Business Combination that may be required or ...

Building on this foundation, bispecific and trispecific antibodies have emerged as innovative biologics aimed at simultaneously engaging multiple targets, promising improved efficacy and safety ...

New research from COMy 2025 reveals a high rate of infections among people with relapsed or refractory multiple myeloma ...

Biogen Inc. and Biogen MA Inc. (“Biogen”) filed a Complaint for Declaratory Judgment and Permanent Injunctive Relief ...

Bispecific antibodies first reached patients as cancer treatments, but a growing number of companies are working to expand these therapies to autoimmune diseases. Sanofi is adding a new contender ...